Tag: Cancer: Leukemia
Risk of Relapse Up for Teens, Young Adults With Leukemia
Increased risk of on-therapy relapse, relapse after completing therapy versus children with ALL
FDA Approves Novel Treatment for Hairy Cell Leukemia
Lumoxiti, a CD22-directed cytotoxin, approved for adults who have had at least two prior therapies
FDA Approves Tibsovo for Acute Myeloid Leukemia
Approved for adults with relapsed or refractory acute myeloid leukemia who have IDH1 mutation
Lymphoma, Leukemia Survivors Have Increased Health Care Use
Survivors who are psychologically distressed use even more services than those who aren't
Leukemia, and Its Treatment, May Pose Neurocognitive Risks
Cerebrospinal fluid biomarkers may identify those at greater risk for poor neuro-related outcomes
Molecular Minimal Disease in Remission Predicts AML Relapse
Persistence of non-DTA mutations during remission linked to rates of relapse, survival
Treatment-Free Remission Feasible After Nilotinib in CML
For patients with chronic myeloid leukemia in chronic phase, TFR is feasible after second-line treatment
TP53 Variants Linked to Childhood ALL, Poor Outcomes
Carrying germline variants linked to decreased event-free, overall survival; higher risk of second cancers
Adipocytes Metabolize, Inactivate Daunorubicin
Adipocytes metabolize daunorubicin to daunorubicinol, reducing its anti-leukemia effect
Zelboraf Approved for Use in Erdheim-Chester Disease
Kinase inhibitor (vemurafenib) for use in patients with BRAF V600 mutation
